RobertEnochLitmanMD

Psychiatry • Rockville, MD

Geriatric Psychiatry

Associate Professor, Psychiatry, Georgetown University School of Medicine

Join to view full profile

Dr. Litman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Litman's full profile

Already have an account?

Office
9605 Medical Center Dr
Suite 270
Rockville, MD 20850
Phone+1 301-251-4702

Fax+1 301-762-5711

Education & Training

National Institutes of Health Clinical CenterResidency, Psychiatry, 1988 - 1989
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1981 - 1984
Albany Medical CenterInternship, Internal Medicine, 1980 - 1981
Albany Medical CollegeClass of 1980

Certifications & Licensure

MD State Medical License 1987 - 2024
DC State Medical License 1989 - 2014
VA State Medical License 2004 - 2008
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

PEARL Schizophrenia Maintenance Start of enrollment: 2011 Sep 01
Completed
Phase 3
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia Start of enrollment: 2014 Mar 26
Completed
Phase 2
Bioavailability of LY03004 and Risperdal® Consta® Start of enrollment: 2014 Sep 01
Completed
Phase 1
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia Start of enrollment: 2020 Jun 16
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Pharmacokinetics and Safety of a Novel Extended-Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder.
David P Walling, Ying Dong, Robert Litman, Wenyan Wang, Chunli Liu
Journal of Clinical Pharmacology. 2024-10-15
Impact of COVID-19 Pandemic on Patients with Serious Mental Illness (SMI) and Nonpsychiatric Control Subjects in Clinical Trials.
Maria Fe Garcia-Rada, Robert E Litman
Innovations in Clinical Neuroscience. 2024-03-01
22 citations
The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
Patricio O'Donnell, Cheng Dong, Venkatesha Murthy, Mahnaz Asgharnejad, Xiaoming Du
Neuropsychopharmacology. 2023-06-01

Journal Articles

Dopamine D2 Receptor Occupancy of Lumateperone (ITI-007): A Positron Emission Tomography Study in Patients with Schizophrenia
Robert E Litman, Dean F Wong, James R Brasic, Nature